targeting tslpr in ph-like and down syndrome-associated all
Published 2 years ago • 119 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
10:31
recent subtypes of all: ph-like all and etp all
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
1:10
target antigens for t-cell engager therapies in all and aml
-
1:06
targeting tcf3-hlf−positive all
-
1:51
targeting complement to treat pnh and other hematologic diseases
-
6:50
a new therapeutic target in t-all
-
1:06
the potential of targeting pak6 in cml
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
1:52
investigating luspatercept utilization patterns in lower-risk mds
-
16:04
acute lymphoblastic leukemia (all) - symptoms, pathogenesis, diagnosis - down syndrome - hematology
-
2:41
safety and efficacy of actaly-cel™ in r/r pediatric b-all
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
8:57
outcomes of sct in t-all and t-lbl
-
2:21
targeting b-cell receptor signaling with btk degraders to treat cll
-
2:44
tct 2021: narsoplimab in ta-tma
-
2:22
improve study: mrd assessment as an endpoint to define treatment length and intensity in cll
-
1:03
personalizing aml treatment by targeting mrd mutations
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
2:24
the effectiveness of ibrutinib flexible dosing regimens on ttnt in cll/sll
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
0:35
tct 2021: what to look forward to